Gena Wang
Stock Analyst at Barclays
(2.40)
# 2,447
Out of 4,931 analysts
213
Total ratings
41.91%
Success rate
-0.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $42 → $56 | $55.50 | +0.90% | 17 | Aug 6, 2025 | |
| BEAM Beam Therapeutics | Maintains: Equal-Weight | $25 → $21 | $18.05 | +16.34% | 10 | Aug 6, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $40 → $31 | $26.79 | +15.71% | 10 | Aug 4, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $329 → $460 | $433.05 | +6.22% | 8 | Aug 1, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Equal-Weight | $10 → $22 | $18.20 | +20.88% | 15 | Jul 30, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $42 → $46 | $50.67 | -9.22% | 16 | Jul 29, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Overweight | $51 → $57 | $40.28 | +41.51% | 10 | Jul 1, 2025 | |
| RNA Avidity Biosciences | Maintains: Overweight | $57 → $59 | $47.67 | +23.77% | 3 | Jun 10, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $15 → $10 | $6.30 | +58.73% | 7 | May 16, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Overweight | $9 → $5 | $0.52 | +867.87% | 4 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $2.74 | +45.99% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $38 | $5.48 | +593.43% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $53 | $34.91 | +51.82% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $8.33 | +32.13% | 10 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $4.72 | +556.78% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $26 | $10.99 | +136.58% | 7 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $435 → $467 | $378.93 | +23.24% | 17 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.50 | +20.24% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $3 → $4 | $8.18 | -51.10% | 8 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $59.81 | +43.79% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $7.82 | +539.39% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $28.13 | +187.95% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $37.34 | +151.77% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $12.15 | -25.93% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $12.01 | +108.16% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $7.91 | +127.70% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $3.28 | +174.39% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $6.32 | +4,251.27% | 1 | Jan 6, 2017 |
CRISPR Therapeutics AG
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $55.50
Upside: +0.90%
Beam Therapeutics
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $18.05
Upside: +16.34%
Moderna
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $40 → $31
Current: $26.79
Upside: +15.71%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $329 → $460
Current: $433.05
Upside: +6.22%
Sarepta Therapeutics
Jul 30, 2025
Upgrades: Equal-Weight
Price Target: $10 → $22
Current: $18.20
Upside: +20.88%
PTC Therapeutics
Jul 29, 2025
Maintains: Equal-Weight
Price Target: $42 → $46
Current: $50.67
Upside: -9.22%
Ionis Pharmaceuticals
Jul 1, 2025
Upgrades: Overweight
Price Target: $51 → $57
Current: $40.28
Upside: +41.51%
Avidity Biosciences
Jun 10, 2025
Maintains: Overweight
Price Target: $57 → $59
Current: $47.67
Upside: +23.77%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $15 → $10
Current: $6.30
Upside: +58.73%
Sangamo Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $5
Current: $0.52
Upside: +867.87%
May 13, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.74
Upside: +45.99%
May 9, 2025
Maintains: Overweight
Price Target: $45 → $38
Current: $5.48
Upside: +593.43%
May 8, 2025
Maintains: Overweight
Price Target: $55 → $53
Current: $34.91
Upside: +51.82%
May 7, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $8.33
Upside: +32.13%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $4.72
Upside: +556.78%
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $10.99
Upside: +136.58%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $378.93
Upside: +23.24%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.50
Upside: +20.24%
Nov 15, 2024
Maintains: Underweight
Price Target: $3 → $4
Current: $8.18
Upside: -51.10%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $59.81
Upside: +43.79%
Aug 5, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $7.82
Upside: +539.39%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $28.13
Upside: +187.95%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $37.34
Upside: +151.77%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $12.15
Upside: -25.93%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $12.01
Upside: +108.16%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $7.91
Upside: +127.70%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $3.28
Upside: +174.39%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $6.32
Upside: +4,251.27%